Former President Donald Trump secured a deal that significantly reduces the cost of GLP-1 weight loss drugs like Ozempic, Wegovy, and Zepbound. This agreement will impact millions of Americans by lowering monthly costs through TrumpRX, a direct-to-consumer platform. The initiative promises substantial savings for consumers, potentially reducing government expenditures through Medicare and Medicaid programs. Pharmaceutical companies stand to face potential financial implications with anticipated losses in profit margins, as seen by a 2-3% drop in stock prices following the announcement. This deal could influence future negotiations on drug pricing, particularly given the CMS’ confirmed initiatives to lower costs across the U.S. healthcare system.